

<b>Section:</b>	<b>General Principles</b>	<b>Standard #: 03.100</b>
<b>Created by:</b>	Province-wide Immunization Program, Standards and Quality	
<b>Approved by:</b>	Province-wide Immunization Program, Standards and Quality	
<b>Approval Date:</b>	February 15, 2018	<b>Revised:</b> June 1, 2023

### **Preamble**

Alberta Health Services (AHS) Province-wide Immunization Program Standards and Quality, Provincial Population and Public Health provides Public Health and other partners who administer provincially funded vaccines with ongoing and timely information relating to province-wide immunization program standards and quality. These standards are based on currently available evidence-based information, Alberta Health (AH) policy, and provincial and national guidelines. Immunizers must be knowledgeable about the specific vaccines they administer.

### **Background**

Immunization is one of the most effective medical interventions to prevent disease. Immunization recommendations are based on scientific knowledge about the vaccine and immune system, epidemiology and burden of disease, vaccine safety, and a cost analysis of preventive measures. The benefits of immunization far outweigh any risks to a vaccine preventable disease (Alberta Immunization Policy, 2016). In the last several decades, immunization has saved more lives in Canada than any other health intervention (AIM, 2007-2015). The establishment of publicly funded immunization programs improves health and saves money.

The *Public Health Act*, Revised Statutes of Alberta 2000 and the Communicable Diseases Regulation, Alberta Regulation 238/1985 with amendments up to and including Alberta Regulation 216/2022 provide the authority for Alberta's Immunization Program. Under this legislation, the Chief Medical Officer of Health (CMOH) is responsible for monitoring the health of Albertans and making recommendations to the Health Minister and AHS on measures to protect and promote the health of the public and to prevent disease and injury. This legislation requires the CMOH to act as a liaison between the government and AHS, Zone Medical Officers of Health (MOHs) and executive officers in the administration of the act. AHS is required to operationalize Alberta's immunization programs. AH is responsible for providing immunization policy and all individuals who administer provincially funded vaccines are expected to follow the Alberta Health policies and guidelines. Public health nurses, under the auspices of the Zone MOH, are accountable for the implementation of immunization programs at the zone level according to provincial requirements.

The AHS immunization policy evolves as new vaccines, research and evidence emerge, with the goal to offer and provide Albertans with protection against vaccine preventable diseases. The Alberta immunization program is guided by recommendations from global, national and local health experts (eg: World Health Organization (WHO), National Advisory Committee on Immunization (NACI), Alberta Advisory Committee on Immunization (AACI)). AACI makes recommendations to the Minister of Health, AH develops the applicable policy and AHS determines how to implement the immunization program in conjunction with AH.

**Literature (Canadian Immunization Guide, Evergreen web version) has shown that low immunization uptake and/or the halting of immunization programs can lead to the resurgence of vaccine preventable communicable diseases. Outbreaks of communicable disease can result in the alteration of the existing immunization schedule.**

## Purpose

The history of provincially funded vaccines used in Alberta provides date ranges for biological products used in Alberta and/or when the product was approved for use in Canada. The objective in compiling this information is to provide immunizers with appropriate data, relative to the Alberta Immunization Program, in order to assess and clarify client immunization needs.

## Applicability

This standard applies to AHS employees who administer and/or handle provincially funded vaccine, AHS Public Health cost recovery vaccine and External providers to whom AHS supplies provincially funded vaccine.

## Definitions

Biological and/or biological products: Refers to any immunizing agent, including vaccines, immunoglobulins and antitoxins.

## Competency

In November 2008, the Public Health Agency of Canada published the Immunization Competencies for Health Professionals with a goal of promoting safe and competent practices for immunization providers. The following competency outlined in that document is applicable to this standard:

- Demonstrates an understanding of the rationale and benefit of immunization, as relevant to the practice setting.

## Section 1: History of Biologicals Administered in Alberta

Biological (Name/Description/Trade Name)	Manufacturer	Vaccine Code	Start Date (YYYY-MMM-DD)	End Date (YYYY-MMM-DD)
Bacillus Calmette-Guérin (TB): BCG Vaccine (freeze-dried)	Connaught	BCG	1956-Jan-01	2007-Aug-09
Botulism Antitoxin	Multiple Manufacturers	BA	1962-Jun-12	
Botulism Antitoxin: Bivalent A & B Botulism Antitoxin: Type E	Connaught /Sanofi Pasteur	BA	Unknown	2011-Oct-26
Botulism Antitoxin – Behring (Equine) Types A, B, & E	Novartis	BA	2011-Oct-27	
Botulism Immune Globulin Intravenous (Human)- BabyBIG®	California Department of Public Health	BAIG	2013-May-27	
COVID-19: mRNA Original (Non-Bivalent) Comirnaty Vaccine 12 Years of Age and Older	Pfizer-BioNTech	COVPBmRNA	2020-Dec-16	
COVID-19: mRNA Bivalent (Original and Omicron BA.4/BA.5) Comirnaty Vaccine 12 Years of Age and Older	Pfizer-BioNTech	COVPBmRNABA45	2022-Oct-24	
COVID-19: mRNA Original (Non-Bivalent) Comirnaty Vaccine 5 Years to 11 Years of Age	Pfizer-BioNTech	COVPB5y-11ymRNA	2021-Nov-26	
COVID-19: mRNA Bivalent (Original and Omicron BA.4/BA.5) Comirnaty Vaccine 5 Years to 11 Years of Age	Pfizer-BioNTech	COVPB5-11mRNA45	2023-Jan-05	

<b>Biological (Name/Description/Trade Name)</b>	<b>Manufacturer</b>	<b>Vaccine Code</b>	<b>Start Date (YYYY-MMM-DD)</b>	<b>End Date (YYYY-MMM-DD)</b>
COVID-19: mRNA Original (Non-Bivalent) Comirnaty Vaccine 6 Months to 4 Years of Age	Pfizer-BioNTech	COVPB6m-4ymRNA	2022-Nov-14	
COVID-19: mRNA Original (Non-Bivalent) SpikeVax Vaccine 12 Years of Age and Older	Moderna	COVMODmRNA	2020-Dec-28	
COVID-19: mRNA Bivalent (Original and Omicron BA.1) SpikeVax Vaccine 18 Years of Age and Older	Moderna	COVMODmRNABA1	2022-Sep-21	
COVID-19: mRNA Original (Non-Bivalent) SpikeVax 6 Years to 11 Years of Age	Moderna	COVMODmRNA	2022-Apr-12	
COVID-19: mRNA Original (Non-Bivalent) SpikeVax Vaccine 6 Months to 5 Years of Age	Moderna	COVMOD6m-5ymRNA	2022-Aug-02	
COVID-19: ChAdOx1-S [recombinant] Vaxzevria	AstraZeneca	COVAUVec	2021-Mar-10	
COVID-19: ChAdOx1-S [recombinant] COVISHIELD	Verity Pharmaceuticals Inc. & Serum Institute of India	COVSIIVec	2021-Mar-10	
COVID-19: Ad26.COVS2.S [recombinant] Janssen	Janssen (Johnson & Johnson)	COVJANVec	2021-Nov-12	
COVID-19: Recombinant Protein, Adjuvanted Novavax (Nuvaxovid)	Novavax Inc.	COVNVASub	2022-Apr-12	
Diphtheria Antitoxin	Multiple Manufacturers	DA	1895-Jan-01	
Diphtheria Antitoxin: ANTIDIPHTHERIA SERUM	Instituto Butantan, Brazil	DA	2006-Mar-08	2010-Oct-31
Diphtheria Antitoxin (equine)	Institute of Immunology Inc Croatia	DA	2011-Apr-21	2014-Mar-31
Diphtheria Antitoxin (equine)	VINS Bioproducts Limited, India	DA	2014-Jun-11	
Diphtheria Antitoxin (equine)	Butantan Institute, Brazil	DA	2023-May-01	
Diphtheria Reaction Test		DRT	1923-Jan-01	1996-Jan-01
Diphtheria Toxoid		Unknown	1930	1994-Aug-01
Diphtheria Toxoid (fluid)		D	1954-Apr-01	1994-Aug-01
Diphtheria Toxoid (fluid-diluted)		DD	1954-Apr-01	1994-Aug-01
Diphtheria Toxoid and Pertussis Combined		No code	1943	1948-Jan-01
Diphtheria/Tetanus Toxoids (pediatric)		DT	1948-Jan-01	1998-Dec-31
Diphtheria/Tetanus/ Acellular Pertussis: TRIPACEL	Connaught/ Aventis Pasteur	DTaP	1997-Jul-01	1999-Jan-01
Diphtheria/Tetanus/ Acellular Pertussis: ADACEL®	Sanofi Pasteur	dTap	2004-Sep-01	

<b>Biological</b> (Name/Description/Trade Name)	<b>Manufacturer</b>	<b>Vaccine Code</b>	<b>Start Date</b> (YYYY-MMM-DD)	<b>End Date</b> (YYYY-MMM-DD)
Diphtheria/Tetanus/ Acellular Pertussis: BOOSTRIX®	GlaxoSmithKline	dTap	2008-Nov-30	
Diphtheria/Tetanus/ Acellular Pertussis/IPV: QUADRACEL®	Connaught/ Sanofi Pasteur	DTaP-IPV	1997-Jul-01	2017-July
Diphtheria/Tetanus/ Acellular Pertussis/IPV: INFANRIX™-IPV	GlaxoSmithKline	DTaP-IPV	2012-Nov-20	2017-Jul
Diphtheria/Tetanus/ Acellular Pertussis/IPV: BOOSTRIX®-IPV	GlaxoSmithKline	dTap-IPV	2012-Oct-11	
Diphtheria/Tetanus/ Acellular Pertussis/IPV/Hib: PENTACEL®	Connaught/ Sanofi Pasteur	DTaP-IPV-Hib	1997-Jul-01	2007-Nov-30
Diphtheria/Tetanus/ Acellular Pertussis/IPV/Hib: PEDIACEL®	Sanofi Pasteur	DTaP-IPV-Hib	2007-Nov-30	
Diphtheria/Tetanus/ Acellular Pertussis/IPV/Hib: INFANRIX™-IPV/Hib	GlaxoSmithKline	DTaP-IPV-Hib	2012-Nov-20	
Diphtheria/Tetanus/Acellular Pertussis/IPV/Hib/Hepatitis B INFANRIX-hexa®	GlaxoSmithKline	DTaP-IPV-Hib-HB	2016-June-01	
Diphtheria/Tetanus/IPV (pediatric)	Connaught	DT-IPV	1996-Jul-01	2005-Oct-01
Diphtheria/Whole Cell Pertussis/Tetanus	Unknown	DPT	1948-Jan-01	1997-Jun-30
Diphtheria/Whole Cell Pertussis/Tetanus/IPV: QUAD	Connaught	DPTP	1994-Aug-02	1997-Jun-30
Diphtheria/Whole Cell Pertussis/Tetanus/IPV/Hib: PENTA	Connaught	DPTPHib	1994-Aug-02	1997-Jun-30
Diphtheria/Whole Cell Pertussis/Tetanus/IPV/ Killed Measles: Quint	Unknown	No code	1968-Jan	1970-Jul
<i>Haemophilus influenzae</i> type b: b-CAPSA	Mead Johnson	Unknown	1987-Aug-01	1987-Oct-01
<i>Haemophilus influenzae</i> type b (PRP)	Connaught	PRP	1987-Oct-01	1988-Mar-01
<i>Haemophilus influenzae</i> type b	Connaught	PRPD	1988-Mar-16 (at 2 years of age) 1998-Apr-04 (at 18 months of age)	1992-May-18
<i>Haemophilus influenzae</i> type b	Merck Frosst	OMP	1990-Jan-01	1994-Aug-02
<i>Haemophilus influenzae</i> type b	Lederle-Praxis	HbOC	1992-May-19	1993-Feb-01
<i>Haemophilus influenzae</i> type b PRPT: Act-HIB®	Connaught/ Sanofi Pasteur	Hib	1993-Feb-01	
<i>Haemophilus influenzae</i> type b: HIBERIX®	GlaxoSmithKline	Hib	2013-Jan-22	

<b>Biological (Name/Description/Trade Name)</b>	<b>Manufacturer</b>	<b>Vaccine Code</b>	<b>Start Date (YYYY-MMM-DD)</b>	<b>End Date (YYYY-MMM-DD)</b>
Hepatitis A – adult: HAVRIX® 1440 and VAQTA®	GlaxoSmithKline and Merck Frosst	HAV	1994-Jan-01	
Hepatitis A - pediatric: HAVRIX® 720 and VAQTA®	GlaxoSmithKline and Merck Frosst	HAV	1997-Jun-01	
Hepatitis A - AVAXIM® Pediatric (outbreak in Edmonton)	Sanofi Pasteur	HAV	2013-Feb	
Hepatitis A & B combined: TWINRIX®	GlaxoSmithKline	HABV	1997-Jan-01	
Hepatitis B: RECOMBIVAX HB® (neonatal program – infants at high risk)	Merck Frosst	HBV	1983-Jan-01	
Hepatitis B: RECOMBIVAX HB® (3 mL multi-dose vials with thimerosal – Grade 5 program)	Merck Canada	HBV	1995-Sep	2010-Oct-31
Hepatitis B: RECOMBIVAX HB® - Thimerosal-free (infants younger than age one)	Merck Frosst	HBTmf	2002-May-01	2011-May-01
Hepatitis B: ENGERIX® B Adult - for individuals allergic to thimerosal	GlaxoSmithKline	HBV	2002	
Hepatitis B: ENGERIX® Pediatric	GlaxoSmithKline	HBV	2011	
Hepatitis B for Dialysis	Merck Frosst	HBVD	1983-Jan-01	
Hepatitis B Immune Globulin	Multiple manufacturers – accessed through Canadian Blood Services	HBIG	1971-Jan-01	
Human Papillomavirus Quadrivalent: GARDASIL® (Grade 5) (Grade 9 catch up 2009-Sep)	Merck Canada	HPV	2008-Sep-01 (girls) 2014-Sep-01 (boys)	2016-Aug-31
Human Papillomavirus 9-Valent GARDASIL®9	Merck Canada	HPV-9	2016-Sep-01	
Immune Serum Globulin (human)	Multiple manufacturers	IG	1987-Feb-18	
Influenza whole cell: FLUVIRAL® & VAXIGRIP®	GlaxoSmithKline and Sanofi Pasteur	FLU	1943-Jan-01	1992 (approx.)
Influenza split virus vaccine: FLUVIRAL® & VAXIGRIP® (first used in Canada approximately 1992). Used in Alberta Influenza program 2005-2011	Biochem/GlaxoSmithKline Connaught/Sanofi Pasteur	FLU	1992 (approx.)	
Influenza H1N1 Pandemic adjuvanted: AREPANRIX™ H1N1 – universal immunization	GlaxoSmithKline	H1N1-09-AD	2009-Oct-19	2010-Oct-31
Influenza H1N1 Pandemic without adjuvant – pregnant women	CSL Australia	H1N1-09	2009-Nov	2009-Nov
Influenza A (H1N1) 2009 Pandemic Monovalent Vaccine	GlaxoSmithKline	H1N1-09	2009-Dec-01	2010-Aug

<b>Biological</b> (Name/Description/Trade Name)	<b>Manufacturer</b>	<b>Vaccine Code</b>	<b>Start Date</b> (YYYY-MMM-DD)	<b>End Date</b> (YYYY-MMM-DD)
(without adjuvant) – pregnant women and individuals 10 to 64 years without immune compromising conditions and who specifically request vaccine without adjuvant				
Influenza Trivalent: AGRIFLU® Used in Alberta Influenza program 2011-2015	Novartis	FLU	2011-Oct	
Influenza Trivalent: FLUAD® Used in Alberta Influenza program 2014-2018	Novartis	FLU	2014-Sep	
Influenza Live attenuated trivalent: FLUMIST® - Pilot/Research 2011-2012 influenza season included 2000 doses	AstraZeneca	FLU	2011-Oct	2012-Mar
Influenza Live attenuated trivalent: FLUMIST®. Used in Alberta Influenza program 2012-2014 (Vaccine of choice for 2-17 years of age)	AstraZeneca	FLU	2012-Oct	2014-May
Influenza Live attenuated: FLUMIST® Quadrivalent Used in Alberta Influenza program 2014-2017 (Vaccine of choice for 2-17 years of age 2014-2016)	AstraZeneca	FLU	2014-Oct	2017-April
Influenza Inactivated Quadrivalent: FLUZONE® multi-dose vial (MDV). Used in Alberta Influenza program 2016-2018	Sanofi Pasteur Inc	FLU	2015-Oct-20	
Influenza Inactivated Quadrivalent: FLUZONE® prefilled syringe. Used in Alberta Influenza program 2015-2018	Sanofi Pasteur Inc	FLU	2015-Oct-20	
Influenza Inactivated Trivalent: INFLUVAC® Used in Alberta Influenza program 2006/2007, 2008/2009, 2015/2016	Abbott Laboratories (BGP Pharma ULC)	FLU	2015-Oct	
E/Z Measles (Live)	Unknown	EZM	1969-Jan-01	1971-Jan-01
Killed Red Measles	Unknown	KMEA	1966	1970-Jul
Measles (Red): Live, single dose catch-up for Grades 1 to 9	Unknown	MEA	1970-Jul	1998-Dec-31
Measles (Red): Live, multi-dose	Unknown		1997-Jan	1997-Dec
Measles/Mumps/Rubella: M-M-R® II (12 months of age routine program)	Merck Frosst	MMR	1982-Oct-01	
Measles/Mumps/Rubella: PRIORIX®	GlaxoSmithKline	MMR	1999 (approx.)	



<b>Biological</b> (Name/Description/Trade Name)	<b>Manufacturer</b>	<b>Vaccine Code</b>	<b>Start Date</b> (YYYY-MMM-DD)	<b>End Date</b> (YYYY-MMM-DD)
Measles/Mumps/Rubella/ Varicella (PRIORIX-TETRA®) – replacing MMR as routine program at 12 months of age	GlaxoSmithKline	MMR-Var	2010-Aug-01	
Measles/Mumps/Rubella/ Varicella (ProQuad™)	Merck Canada	MMR-Var	2014-May-13	
Measles/Rubella (second dose measles catch-up, Grades 1 to 9)	Unknown	MR	1997-Jan-01	1999-Apr-30
Meningococcal B Multicomponent Recombinant Vaccine: BEXSERO®	Novartis Vaccines and Diagnostics Inc.	Men-B	2014-Sep-23	
Meningococcal Conjugate monovalent C (Campaign: 2 to 24 months of age)	Unknown	MenconC	2001-Nov-01	2002-Mar- 31
Meningococcal Conjugate - monovalent C (Universal Infant Program for infants born on or after 2001/Sep/01) Menjugate®	Novartis	MenconC	2002-Apr-04	Unknown
Meningococcal Conjugate - monovalent C: NeisVacC®	GlaxoSmithKline	MenconC	2005-Oct	
Meningococcal Conjugate Polysaccharide (A,C,Y,W-135) (Menactra®) - High-risk Groups	Sanofi Pasteur	MenC-ACYW	2007-Feb-01	
Meningococcal (A,C, W-135, Y) Conjugate: (MENVEO™)	Novartis	MenC-ACYW	2011-Feb	
Meningococcal (Groups A, C, W-135 and Y) Conjugate: (Nimenrix®)	GlaxoSmithKline	MenC-ACYW	2017-Sep	
Meningococcal Polysaccharide Bivalent A,C (Campaign – 2 to 24 years of age)	Unknown	MenAC MeninAC	2001-Feb-06	2002-Mar- 01
Meningococcal polysaccharide (quadrivalent A, C, Y, W-135) – high-risk groups (MENOMUNE®)	Connaught/ Sanofi Pasteur	MENING-P	1983-May-04	2012-Jan-18
Meningococcal Polysaccharide (quadrivalent A,C, Y, W-135) - Campaign	Unknown	MENING-P (single dose) MENOTET (multi- dose)	2000-Feb-15	2002-Mar- 01
Mumps: MUMPSVAX	Merck Frosst	MU	1982-Jan-01	2004-Feb- 08
Pertussis Acellular – Acel-P	Wyeth-Ayerst	aP	1997-Jul-01	2001-Oct
Pertussis Whole Cell	Unknown	P	1939-Jan-01	1997-Jun-30
Pneumococcal Conjugate – 7 Valent: PREVNAR® (routine infant program: 4 dose series)	Wyeth	PNEU-C	2002-Sep-01	2010-Jun-30
Pneumococcal Conjugate – 13 Valent: PREVNAR® (replaced 7 valent vaccine for infant program: 3 dose series; catch-	Wyeth	PNEU-C13	2010-Jul-01	

<b>Biological (Name/Description/Trade Name)</b>	<b>Manufacturer</b>	<b>Vaccine Code</b>	<b>Start Date (YYYY-MMM-DD)</b>	<b>End Date (YYYY-MMM-DD)</b>
up program: single dose at 4-6 years)				
Pneumococcal Polysaccharide: PNEUMOVAX® 23	Merck Frosst	PNEUMO-P	1997-Apr (high-risk groups) 1998-Sep (65 years of age and older)	
Pneumococcal Polysaccharide: Pneumo 23®	Sanofi Pasteur	PNEUMO-P	1997-Apr	2008-Sep
Polio Inactivated (Salk)-vaccine trials: pre-licensure		IPV	1954	Unknown
Polio Inactivated (Salk)	Unknown	IPV	1956-Jan-01	
Polio Inactivated (Salk) diploid cell	Unknown	IPV	Unknown (vaccine introduced in Canada 1989)	2007-Apr-30
Polio Inactivated (Salk) Vero cell Origin: IMOVAX® Polio	Sanofi Pasteur	IPV	2007-Apr-09	
Polio Oral (Sabin)	Connaught	OPV	1962-Jan-01	1994-Jul-31
Rabies Vaccine	Multiple manufacturers	RAB	1980-Jan-01	
Rabies HDCV: IMOVAX® Rabies	Sanofi Pasteur	RAB	1999-Aug (approx.)	
Rabies PCECV: RabAvert®	Novartis	RAB	2005-Jun-01	
Rabies Immune Globulin	Multiple manufacturers	RIG	1983-Sep-16	
Rabies Immune Globulin: IMOAM® Rabies	Sanofi Pasteur	RIG	2004 - 2005	
Rabies Immune Globulin: HYPERRAB® S/D	Talecris Therapeutics/ Grifols Therapeutics	RIG	2007-Jul	
Rotavirus vaccine: ROTARIX®	GSK	ROT	2015-Jun-01 2021-May-01	2018-Jun
Rotavirus Vaccine: Rotateq®	Merck Canada Inc.	ROT	2018-May	2022-Jul-29
Rubella	Connaught	RUB	1971-Jan-01	1998-Oct-01
Smallpox (vaccinia) - universal	Unknown	Sma	1870-Jan-01	1980-Apr-10
Smallpox (vaccinia) – select groups	Unknown	Sma	2005-Jan-01	Unknown
Smallpox and Monkeypox Vaccine: Imvamune®	Bavarian Nordic A/S	SMAMONV	2022-Jun-07	
Smallpox Antiviral TPOXX® Tecvirimat Capsules	SIGA Technologies Inc. (USA Distributor: Innomar Strategies Inc)	NA	2022-Jun-07	
Snakebite Antivenom	Unknown	SNAKE	1980-Jan-01	2002-Mar-20
Tetanus/Diphtheria Toxoids (adults)	Sanofi Pasteur	Td	1980-Jul-09	2022-Jun-30
Tetanus Immune Globulin (Human)	Multiple	TIG	Unknown	2006-Jun



Biological (Name/Description/Trade Name)	Manufacturer	Vaccine Code	Start Date (YYYY-MMM-DD)	End Date (YYYY-MMM-DD)
	manufacturers			
Tetanus Immune Globulin (Human): HYPERTET® S/D	Talecris Therapeutics/ Grifols Therapeutics	TIG	2006-Jul	
Tetanus/Diphtheria/IPV (adult)	Sanofi Pasteur Limited	TdP	2015-Feb-11	
Tetanus Polio	Unknown	TP	1959-Jan-01	1994-Aug-01
Tetanus Toxoid	Unknown	TT	1947-Jan-01	2000-Dec-31
Tuberculin Purified Protein Derivative 5TU (Mantoux – TB Test)	Connaught/ Sanofi Pasteur	PPD	1960-Jan-05	
Typhoid injectable: TYPHERIX®	GlaxoSmithKline	TYVI	2004-Jan-19	
Typhoid injectable: TYPHIMVi®	Sanofi Pasteur S/A	TYVI	2013-Sep-04	
Varicella Zoster: VARIVAX® II and III (one year of age – phased in approach)	Merck Frosst	VZ	2001-Jul-01	
Varicella Zoster: VARILRIX®	GlaxoSmithKline	VZ	Unknown	
Varicella Immune Globulin	Multiple manufacturers – Accessed through Canadian Blood Services	VZIG	1985-Jan-01	

## Notes

- Not all vaccine manufacturers are known or multiple manufacturers have supplied the biological product to Alberta Health (Alberta Ministry of Health) over the years since first introduced.
- For additional information, refer to the manufacturer of the product and/or Health Canada.

## References

1. Alberta Health. Public Health and Compliance Division, Alberta Immunization Policy History of Biologicals in Alberta (2022, June 30).
2. Alberta Health. (2016, February). *Immunization Data Submission and Response Guidelines, Version 5.8*. <http://www.health.alberta.ca/documents/Immunization-Data-Submission-Guidelines-2016.pdf>
3. Alberta Health and Wellness, Disease Control and Prevention. (2004, May). *Alberta's Meningococcal Immunization Program: A full report*. [www.health.alberta.ca/documents/Meningococcal-Campaign-2001.pdf](http://www.health.alberta.ca/documents/Meningococcal-Campaign-2001.pdf)
4. AHS (former Calgary Health Region), Communicable Disease Control. (2005, November). *Dates when new programs, vaccines, etc. adopted by Calgary Health Region*.
5. AHS (former Capital Health Region), Public Health Division, Communicable Disease Control. (2002, December). Biologicals introduced in Alberta. In *Communicable Disease Control Manual* (Appendix 4).
6. Waters, John. (1996). *Biologicals introduced in Alberta*. Unpublished personal file.